Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Citi
Medtronic
Fish and Richardson
Mallinckrodt
Merck
Cantor Fitzgerald
Baxter
AstraZeneca

Generated: January 17, 2018

DrugPatentWatch Database Preview

PREVACID Drug Profile

« Back to Dashboard

Which patents cover Prevacid, and when can generic versions of Prevacid launch?

Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Glaxosmithkline Cons. and is included in six NDAs. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-three patent family members in nineteen countries.

The generic ingredient in PREVACID is lansoprazole; naproxen. There are fifty-four drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.
Drug patent expirations by year for PREVACID
Pharmacology for PREVACID

US Patents and Regulatory Information for PREVACID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-001 May 10, 1995 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-002 May 3, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-002 Aug 30, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Na PREVACID NAPRAPAC 375 (COPACKAGED) lansoprazole; naproxen CAPSULE, DELAYED REL PELLETS, TABLET;ORAL 021507-003 Nov 14, 2003 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Na PREVACID IV lansoprazole INJECTABLE;INTRAVENOUS 021566-001 May 27, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-002 May 10, 1995 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-001 May 3, 2001 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PREVACID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-002 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-001 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-001 May 10, 1995 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL 021428-002 Aug 30, 2002 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-002 May 10, 1995 ➤ Subscribe ➤ Subscribe
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-001 May 3, 2001 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-001 May 10, 1995 ➤ Subscribe ➤ Subscribe
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-001 May 3, 2001 ➤ Subscribe ➤ Subscribe
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-001 May 3, 2001 ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa PREVACID lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 020406-001 May 10, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PREVACID
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Delayed-release Orally Disinte 15 mg and 30 mg ➤ Subscribe 12/27/2006
➤ Subscribe Delayed-release Pellets/Capsul 15 mg and 30 mg ➤ Subscribe 12/5/2005

Non-Orange Book US Patents for PREVACID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,070,805 Rapidly disintegrable solid preparation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PREVACID

Supplementary Protection Certificates for PREVACID

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0021 Belgium ➤ Subscribe PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
C0021 Belgium ➤ Subscribe PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
14/008 Ireland ➤ Subscribe PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Julphar
Moodys
McKesson
Medtronic
Farmers Insurance
Express Scripts
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot